Successful Treatment with Sulbactam-Durlobactam for Severe Acute Pancreatitis Complicated by Extensively
Zhengmao Ge1, Li Li1, Longxin Wang1
1Department of Critical Care Medicine, The 967 Hospital, Joint Logistics Support Force of PLA, Dalian, 116021, People's Republic of China.
Background:
The management of severe acute pancreatitis (SAP) complicated by multi-site infections with extensively drug-resistant Acinetobacter baumannii (XDR-AB) represents a critical therapeutic challenge. This report describes, to our knowledge, an early successful application of sulbactam-durlobactam in an SAP patient with concurrent XDR-AB infections in the abdomen, biliary tract and lungs.
Case Presentation:
A 36-year-old female with hypertriglyceridemic SAP developed infections at multiple sites, with cultures consistently yielding XDR-AB. After the failure of multiple last-line antimicrobial regimens, therapy was switched to sulbactam-durlobactam combined with meropenem. This change was followed by a substantial clinical improvement: body temperature normalized, infection biomarkers decreased significantly and microbiological clearance of XDR-AB from all sites was achieved, leading to successful liberation from mechanical ventilation and discharge from the ICU.
Conclusion:
This case demonstrates that sulbactam-durlobactam can be a highly effective therapeutic option for achieving both clinical and microbiological cure in complex SAP cases with multi-site XDR-AB infections that are refractory to conventional treatment regimens. It contributes early real-world evidence supporting a new therapeutic strategy for managing such life-threatening, complex infections.
Insights
This case study highlights the successful use of sulbactam-durlobactam for severe acute pancreatitis (SAP) with extensively drug-resistant Acinetobacter baumannii (XDR-AB) infections. The new treatment achieved clinical and microbiological cure in a patient refractory to other therapies.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pharmacology
Background:
- Severe acute pancreatitis (SAP) with multi-site infections caused by extensively drug-resistant Acinetobacter baumannii (XDR-AB) presents significant treatment challenges.
- Conventional antimicrobial regimens often fail in these complex cases, necessitating novel therapeutic approaches.
More Related Videos
03:42Author Spotlight: Advancements in Retroperitoneal Approach for Necrotizing Pancreatitis
Published on: March 15, 2024
05:06Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
Published on: January 5, 2024
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Pyelonephritis I: Introduction
Acute Pyelonephritis II: Diagnostic Studies and Management
Clinical Significance of Antibiotic Resistance
Acute Pancreatitis I: Introduction
